FDA Advisory Panel Votes Against Implantable CardioMEMS HF Pressure Measurement System Reply

Members of the FDA Circulatory System Devices Panel today recommended against approval of the implantable CardioMEMS HF Pressure Measurement System. Although panel members agreed that the device was safe by a 9-1 vote, they voted 7-3 that the device had not been shown to be effective and 6-4 that the benefits did not outweigh the risks.

Panel discussion focused on the CHAMPION trial. In an extraordinary addendum to its main review of the trial, the FDA reviewers raised serious concerns that “the conduct of the trial may have biased the study results.” An audit of the trial by FDA inspectors determined that the sponsor or the principal investigators “routinely contacted investigational sites and made specific therapeutic recommendations for some Treatment Group study subjects.”

As previously reported here and here, Wells Fargo analyst Larry Biegelsen was the first to uncover the news that the FDA would raise serious questions about the CHAMPION trial at the advisory panel. These initial charges were dismissed by Jay Yadav, the cardiologist who founded the company, but the concerns about CHAMPION now appear to be valid.



What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s